Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Immune modulation and chronic graft-versus-host disease

Bone Marrow Transplantation volume 42, pages S66–S69 (2008)Cite this article

Abstract

As more and more patients undergoing allogeneic hematopoietic SCT (HSCT) survive the early post-transplant period, the number of individuals at risk for chronic GVHD has grown. Treatment for established cGVHD remains unsatisfactory. No experimental agent has demonstrated superiority to steroids alone in a randomized clinical trial. Distinguishing chronic from acute graft-versus-host disease is a major issue. The importance of achieving clarity in cGVHD diagnosis is critical as efforts are undertaken to understand its pathogenesis and to design definitive trials that can target prevention and/or treatment. Immune tolerance to self-antigens may be broken in cGVHD, giving rise to the autoimmune manifestations of the disorder. Recent attention has focused on CD4+CD25 regulatory T cells and their relationship to cGVHD. Significant enthusiasm has emerged for manipulating Treg either ex vivo or in vivo for clinical benefit. Another immunomodulatory approach to cGVHD might be the targeting of B lymphocytes and the antibodies they produce. As efforts continue to devise strategies to treat and prevent chronic GVHD, it is important to acknowledge the link between cGVHD and freedom from relapse, at least for certain malignancies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Lee SJ, Klein JP, Barrett AJ et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406–414.

    Article  CAS  PubMed  Google Scholar 

  2. Socie G, Stone JV, Wingard JR et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late effects working committee of the international bone marrow transplant registry. N Engl J Med 1999; 341: 14–21.

    Article  CAS  PubMed  Google Scholar 

  3. Lee SJ, Kim HT, Ho VT et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant 2006; 38: 305–310.

    Article  CAS  PubMed  Google Scholar 

  4. Fraser CJ, Bhatia S, Ness K et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 2006; 108: 2867–2873.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH . Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685–3691.

    Article  CAS  PubMed  Google Scholar 

  6. Schmitz N, Eapen M, Horowitz MM et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the international bone marrow transplant registry and the european group for blood and marrow transplantation. Blood 2006; 108: 4288–4290.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Lee SJ, Vogelsang G, Flowers ME . Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215–233.

    Article  CAS  PubMed  Google Scholar 

  8. Akpek G, Lee SM, Anders V, Vogelsang GB . A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001; 7: 495–502.

    Article  CAS  PubMed  Google Scholar 

  9. Arora M, Wagner JE, Davies SM et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001; 7: 265–273.

    Article  CAS  PubMed  Google Scholar 

  10. Lopez F, Parker P, Nademanee A et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 307–313.

    Article  CAS  PubMed  Google Scholar 

  11. Busca A, Locatelli F, Marmont F, Audisio E, Falda M . Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica 2003; 88: 837–839.

    PubMed  Google Scholar 

  12. Bolaños-Meade J, Jacobsohn D, Anders V et al. Pentostatin in steroid-refractory chronic graft-versus-host disease. Blood 2005; 106: 513A–514A.

    Google Scholar 

  13. Goldberg JD, Jacobsohn DA, Margolis J et al. Pentostatin for the treatment of chronic graft-versus-host disease in children. J Pediatr Hematol Oncol 2003; 25: 584–588.

    Article  PubMed  Google Scholar 

  14. Couriel DR, Saliba R, Escalon MP et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005; 130: 409–417.

    Article  CAS  PubMed  Google Scholar 

  15. Johnston LJ, Brown J, Shizuru JA et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 47–55.

    Article  CAS  PubMed  Google Scholar 

  16. Couriel DR, Hosing C, Saliba R et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006; 107: 3074–3080.

    Article  CAS  PubMed  Google Scholar 

  17. Foss FM, DiVenuti GM, Chin K et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 2005; 35: 1187–1193.

    Article  CAS  PubMed  Google Scholar 

  18. Greinix HT, Volc-Platzer B, Rabitsch W et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098–3104.

    CAS  PubMed  Google Scholar 

  19. Carnevale-Schianca F, Martin P, Sullivan K et al. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6: 613–620.

    Article  CAS  PubMed  Google Scholar 

  20. Filipovich AH, Weisdorf D, Pavletic S et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  21. Pavletic SZ, Martin P, Lee SJ et al. Measuring therapeutic response in chronic graft-versus-host disease: National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response criteria working group report. Biol Blood Marrow Transplant 2006; 12: 252–266.

    Article  PubMed  Google Scholar 

  22. Martin PJ, Weisdorf D, Przepiorka D et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. Design of clinical trials working group report. Biol Blood Marrow Transplant 2006; 12: 491–505.

    Article  PubMed  Google Scholar 

  23. Ho V, Soiffer RJ . The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3192–3204.

    Article  CAS  PubMed  Google Scholar 

  24. Ochs LA, Miller WJ, Filipovich AH et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transplant 1994; 13: 455–460.

    CAS  PubMed  Google Scholar 

  25. Perez-Simon JA, Kottaridis PD, Martino R et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121–3127.

    Article  CAS  PubMed  Google Scholar 

  26. Bacigalupo A, Lamparelli T, Barisione G et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560–565.

    Article  PubMed  Google Scholar 

  27. Basara N, Baurmann H, Kolbe K et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005; 35: 1011–1018.

    Article  CAS  PubMed  Google Scholar 

  28. Pavletic SZ, Carter SL, Kernan NA et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005; 106: 3308–3313.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ehrenstein MR, Evans JG, Singh A et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy. J Exp Med 2004; 200: 277–285.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA . Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971–979.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Miyara M, Amoura Z, Parizot C et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005; 175: 8392–8400.

    Article  CAS  PubMed  Google Scholar 

  32. Rieger K, Loddenkemper C, Maul J et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006; 107: 1717–1723.

    Article  CAS  PubMed  Google Scholar 

  33. Anderson BE, McNiff JM, Matte C, Athanasiadis I, Shlomchik WD, Shlomchik MJ . Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 2004; 104: 1565–1573.

    Article  CAS  PubMed  Google Scholar 

  34. Zorn E, Kim HT, Lee SJ et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005; 106: 2903–2911.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Clark FJ, Gregg R, Piper K et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004; 103: 2410–2416.

    Article  CAS  PubMed  Google Scholar 

  36. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Dunn DH . Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117: 2570–2582.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Nguyen VH, Zeiser R, Dasilva DL et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 2007; 109: 2649–2656.

    Article  CAS  PubMed  Google Scholar 

  38. Rieger K, Loddenkemper C, Maul J et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006; 107: 1717–1723.

    Article  CAS  PubMed  Google Scholar 

  39. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR . Absence of regulatory T cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft versus host disease. Blood 2007; 110: 3804–3813.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I . Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006; 107: 1018–1023.

    Article  CAS  PubMed  Google Scholar 

  41. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A . Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007; 178: 320–329.

    Article  CAS  PubMed  Google Scholar 

  42. Peritt D . Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 7–12.

    Article  CAS  PubMed  Google Scholar 

  43. Meloni F, Cascina A, Miserere S, Perotti C, Vitulo P, Fietta AM . Peripheral CD4(+)CD25(+) TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients. Transplant Proc 2007; 39: 213–217.

    Article  CAS  PubMed  Google Scholar 

  44. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY . A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142–1151.

    Article  CAS  PubMed  Google Scholar 

  45. Zhang H, Chua KS, Guimond M et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005; 11: 1238–1243.

    Article  CAS  PubMed  Google Scholar 

  46. Sereti I, Imamichi H, Natarajan V et al. In vivo expansion of CD4 CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005; 115: 1839–1847.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Zorn E, Nelson EA, Mohseni M et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108: 1571–1579.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Patriarca F, Skert C, Sperotto A et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 2006; 34: 389–396.

    Article  CAS  PubMed  Google Scholar 

  49. Svegliati Baroni S, Olivieri A, Campelli N et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007; 110: 237–241.

    Article  Google Scholar 

  50. Zhang C, Todorov I, Zhang Z et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006; 107: 2993–3001.

    Article  CAS  PubMed  Google Scholar 

  51. Srantopoulos S et al. High levels of B cell activating factor (BAFF) in patients with active chronic graft versus host disease. Clin Cancer Res 2007; 13: 6107–6114.

    Article  Google Scholar 

  52. Miklos DB, Kim HT, Miller KH et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105: 2973–2978.

    Article  CAS  PubMed  Google Scholar 

  53. Cutler C, Miklos D, Kim HT et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756–762.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Zaja F, Bacigalupo A, Patriarca F et al. Treatment of chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007; 40: 273–277.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA, USA

    R J Soiffer

Authors
  1. R J Soiffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R J Soiffer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Soiffer, R. Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant 42 (Suppl 1), S66–S69 (2008). https://doi.org/10.1038/bmt.2008.119

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.119

Keywords

This article is cited by

Search

Advanced search

Quick links